Loading
CBB-120 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.
AACR-NCI-EORTC 2025 abstract A124 describes CBB-120 with EGCit linkers and TOP1/ATR inhibitor payloads. Evidence includes cell assays, xenografts and cynomolgus-monkey toxicology. Tumor regressions and comparisons with single-payload ADCs were in models, not a randomized clinical comparison. On-target skin toxicity was observed in monkeys; clinical benefit and safety remain unestablished.
Site-specific, Fc-silenced anti-TROP2 ADC delivering a TOP1 inhibitor and an ATR inhibitor to combine DNA damage with inhibition of its repair. Connects to TROP2.
1.CBB-120's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CBB-120" OR ABSTRACT:"CBB-120") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CBB-120, not a curated reading list.
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/